Theravance Biopharma, Inc. Amortization of Debt Issuance Costs
Theravance Biopharma, Inc. (TBPH) reported Amortization of Debt Issuance Costs of $536.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2023-03-01
- Theravance Biopharma, Inc. amortization of debt issuance costs for fiscal 2022 was $536.00K, a 50.00% decline from fiscal 2021.
- Theravance Biopharma, Inc. amortization of debt issuance costs for fiscal 2021 was $1.07M, a 0.00% change from fiscal 2020.
- Theravance Biopharma, Inc. amortization of debt issuance costs for fiscal 2020 was $1.07M, a 64.86% decline from fiscal 2019.
- Theravance Biopharma, Inc. amortization of debt issuance costs for fiscal 2019 was $3.05M, a 161.66% increase from fiscal 2018.
| Period end | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 12 month as first filed |
|---|---|---|
| 2022-12-31 | $536.00K 10-K · filed 2023-03-01 | |
| 2021-12-31 | $1.07M 10-K · filed 2023-03-01 | $2.18M 10-K · filed 2022-02-28 |
| 2020-12-31 | $1.07M 10-K · filed 2023-03-01 | $1.96M 10-K · filed 2021-02-26 |
| 2019-12-31 | $3.05M 10-K · filed 2022-02-28 | |
| 2018-12-31 | $1.17M 10-K · filed 2021-02-26 | |
| 2017-12-31 | $1.07M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $179.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |